Fengcai Zhu

InstitutionJiangsu provincial Center for Disease Control and Prevention
AddressNanjing
Jiangsu
China
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 21 Covid-19 publications, with a maximum of 3 publications in April 2021
    All Publications
    Bar chart showing 170 publications over 19 distinct years, with a maximum of 24 publications in 2015
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Jiang HD, Tao YY, Jia SY, Li JX, Zhu FC. Coronavirus disease 2019 vaccines: landscape of global studies and potential risks. Chin Med J (Engl). 2021 Aug 02; 134(17):2037-2044. PMID: 34343152.
      Citations:    Fields:    Translation:Humans
    2. Meng FY, Gao F, Jia SY, Wu XH, Li JX, Guo XL, Zhang JL, Cui BP, Wu ZM, Wei MW, Ma ZL, Peng HL, Pan HX, Fan L, Zhang J, Wan JQ, Zhu ZK, Wang XW, Zhu FC. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct Target Ther. 2021 07 15; 6(1):271. PMID: 34267185.
      Citations: 1     Translation:HumansCTClinical Trials
    3. Jiang HD, Zhang L, Li JX, Zhu FC. Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines. Engineering (Beijing). 2021 Jul; 7(7):903-907. PMID: 34123472.
      Citations:    
    4. Pan HX, Liu JK, Huang BY, Li GF, Chang XY, Liu YF, Wang WL, Chu K, Hu JL, Li JX, Zhu DD, Wu JL, Xu XY, Zhang L, Wang M, Tan WJ, Huang WJ, Zhu FC. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chin Med J (Engl). 2021 Apr 28; 134(11):1289-1298. PMID: 33928916.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    5. Ge Y, Tian T, Huang S, Wan F, Li J, Li S, Wang X, Yang H, Hong L, Wu N, Yuan E, Luo Y, Cheng L, Hu C, Lei Y, Shu H, Feng X, Jiang Z, Wu Y, Chi Y, Guo X, Cui L, Xiao L, Li Z, Yang C, Miao Z, Chen L, Li H, Zeng H, Zhao D, Zhu F, Shen X, Zeng J. An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. Signal Transduct Target Ther. 2021 04 24; 6(1):165. PMID: 33895786.
      Citations: 16     Translation:Humans
    6. Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, Ji R, Lin M, Zhu Z, Türeci Ö, Lagkadinou E, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Sahin U, Zhu L, Zhu F. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070. PMID: 33888900.
      Citations: 19     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    7. Zhao D, Xu W, Zhang X, Wang X, Ge Y, Yuan E, Xiong Y, Wu S, Li S, Wu N, Tian T, Feng X, Shu H, Lang P, Li J, Zhu F, Shen X, Li H, Li P, Zeng J. Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2. Protein Cell. 2021 09; 12(9):734-740. PMID: 33770364.
      Citations: 3     Fields:    Translation:Humans
    8. Li JX, Zhu FC. Adjuvantation helps to optimise COVID-19 vaccine candidate. Lancet Infect Dis. 2021 07; 21(7):891-893. PMID: 33705726.
      Citations: 5     Fields:    Translation:Humans
    9. Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021 02 02; 6(1):48. PMID: 33531462.
      Citations: 18     Translation:HumansPHPublic Health
    10. Milewska A, Chi Y, Szczepanski A, Barreto-Duran E, Dabrowska A, Botwina P, Obloza M, Liu K, Liu D, Guo X, Ge Y, Li J, Cui L, Ochman M, Urlik M, Rodziewicz-Motowidlo S, Zhu F, Szczubialka K, Nowakowska M, Pyrc K. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV. J Virol. 2021 01 28; 95(4). PMID: 33219167.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    11. Wang N, Sun Y, Feng R, Wang Y, Guo Y, Zhang L, Deng YQ, Wang L, Cui Z, Cao L, Zhang YJ, Li W, Zhu FC, Qin CF, Wang X. Structure-based development of human antibody cocktails against SARS-CoV-2. Cell Res. 2021 01; 31(1):101-103. PMID: 33262454.
      Citations: 23     Fields:    Translation:Humans
    12. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 02; 21(2):181-192. PMID: 33217362.
      Citations: 278     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    13. Zhang L, Zheng B, Gao X, Zhang L, Pan H, Qiao Y, Suo G, Zhu F. Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis. Front Immunol. 2020; 11:595970. PMID: 33281824.
      Citations: 4     Fields:    Translation:HumansCells
    14. Chen W, Zhu FC. Challenges in the Development of a Vaccine Against COVID-19. Engineering (Beijing). 2020 Oct; 6(10):1067-1069. PMID: 32953196.
      Citations:    
    15. Bao C, Pan E, Ai J, Dai Q, Xu K, Shi N, Gao Q, Hu J, Peng Z, Huang H, Jin H, Zhu F. COVID-19 outbreak following a single patient exposure at an entertainment site: An epidemiological study. Transbound Emerg Dis. 2021 Mar; 68(2):773-781. PMID: 32725765.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    16. Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, Liu J, Guo X, Huang C, Jiao Y, Zhu F, Zhu B, Cui L. Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China. J Infect Dis. 2020 08 04; 222(5):746-754. PMID: 32563194.
      Citations: 83     Fields:    Translation:HumansCellsPHPublic Health
    17. Wu T, Ge Y, Zhao K, Zhu X, Chen Y, Wu B, Zhu F, Zhu B, Cui L. A reverse-transcription recombinase-aided amplification assay for the rapid detection of N gene of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). Virology. 2020 10; 549:1-4. PMID: 32758712.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    18. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XW, Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488. PMID: 32702299.
      Citations: 361     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    19. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 06 13; 395(10240):1845-1854. PMID: 32450106.
      Citations: 442     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    20. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, Zhu F, Zhu B, Cui L. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020 08; 285:198005. PMID: 32408156.
      Citations: 134     Fields:    Translation:HumansCellsPHPublic Health
    21. Shi F, Wu T, Zhu X, Ge Y, Zeng X, Chi Y, Du X, Zhu L, Zhu F, Zhu B, Cui L, Wu B. Association of viral load with serum biomakers among COVID-19 cases. Virology. 2020 07; 546:122-126. PMID: 32452410.
      Citations: 21     Fields:    Translation:HumansCellsPHPublic Health
    Zhu's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (252)
    Explore
    _
    Co-Authors (224)
    Explore
    _
    Similar People (60)
    Explore
    _